Mutual Advisors’s TG Therapeutics TGTX Stock Holding History

Mutual Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4,845	Closed	-$234K	–	853
2021 Q1	$234K	Buy	+4,845	New	+$233K	0.02%	684

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Mutual Advisors's TGTX Position: Q2 2021 in Review

Mutual Advisors sold out of TG Therapeutics (TGTX) in Q2 2021, closing a stake of 4,845 shares — an estimated $234K sold.

Mutual Advisors first reported a position in TGTX in Q1 2021 and held it in 1 quarter. The position peaked at $234K in Q1 2021. 237 funds tracked by Wall St. Rank hold TGTX as of Q2 2021.

Mutual Advisors reported no remaining TG Therapeutics position as of Q2 2021 after selling out during the quarter.
Mutual Advisors sold 4,845 TG Therapeutics shares in Q2 2021, an estimated $234K.
Mutual Advisors first reported a position in TG Therapeutics in Q1 2021 and held it in 1 quarter.
Mutual Advisors's TG Therapeutics position peaked at $234K in Q1 2021.
237 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2021.

Based on Mutual Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.